Skip to main content
AmigoFish

Genmab and AbbVie’s Epkinly win, a rush of deals, Sarepta’s turnaround hopes, more

From BioSpace · · 24 min

This plays from the publisher's own server. We do not host a copy.

Open at the source

Not rated yet

Description

New data for Genmab and AbbVie’s bispecific antibody Epkinly wowed analysts and could set the partners up for an expanded approval in diffuse large B cell lymphoma; deals have flowed steadily this week, including Novartis’ nearly $8 billion bet on mRNA drugs with China’s Abogen Biosciences; and could Sarepta Therapeutics turn things around from last year’s annus horribilis?

Back to BioSpace · Report a problem